Assessing physostigmine's contraindication in cyclic antidepressant ingestions

Area of Science:

• Toxicology
• Emergency Medicine
• Clinical Pharmacology

Background:

• Physostigmine is an antidote for antimuscarinic toxicity.
• Cyclic antidepressant (TCA) ingestion and QRS prolongation are commonly cited contraindications for physostigmine use.
• Historical use of physostigmine as a first-line antidote for TCA overdose has been overshadowed by case reports of asystole.

Purpose of the Study:

• To evaluate the appropriateness of contraindicating physostigmine in all cyclic antidepressant ingestions.
• To review the evidence regarding the safety and efficacy of physostigmine in the context of TCA overdose and electrocardiographic changes.

Main Methods:

• Systematic review of published clinical and experimental evidence.
• Analysis of case reports and studies investigating physostigmine's effects in TCA toxicity.
• Evaluation of electrocardiographic criteria and TCA ingestion as contraindications.

Main Results:

• Limited evidence supports the contraindication of physostigmine based solely on TCA ingestion.
• Electrocardiographic criteria, such as QRS prolongation, may not reliably predict adverse events with physostigmine.
• Historical data suggests physostigmine was previously considered a viable treatment option.

Conclusions:

• The contraindication of physostigmine in all cyclic antidepressant ingestions appears unwarranted.
• Clinical and experimental evidence does not strongly support using electrocardiographic criteria or TCA ingestion to contraindicate physostigmine.
• Re-evaluation of physostigmine's role as an antidote in TCA toxicity is warranted.